Vaccine agreements between the Commission and pharmaceutical companies

Vaccine agreements between the Commission and pharmaceutical companies

On 1 September 2020, German Member of the European Parliament (MEP) Martin Schirdewan of The Left group in the European Parliament – GUE/NGL posed a written parliamentary question to the European Commission:

“1. Can the Commission provide details of its advance purchase agreement with AstraZeneca and its potential contracts with Moderna, Sanofi-GSK, Johnson & Johnson and CureVac, such as the payment amounts, the payment schedule, the price per person vaccinated, the quantity of vaccines and the delivery timeline after approval (if the vaccine is successful)?

2. Will its partner pharmaceutical corporations profit from the agreement and potential contracts, and if so, how much profit will they earn?

3. Which experts have been appointed by the Member States to the steering boards for the agreements?”

On 22 January 2021, Health and Food Safety Commissioner Stella Kyriakides responded on behalf of the European Commission stating: “The European Commission together with Member States has engaged in intensive negotiations with several vaccine manufacturers to secure the best possible agreements so that vaccines are affordable, safe, and available to Member States.

The Commission published information on contracts with: AstraZeneca, Sanofi-GSK and Johnson&Johnson, BioNTech-Pfizer CureVac, and Moderna. Specific information on the contracts is protected for confidentiality reasons, which is warranted by the highly competitive nature of this global market.

Disclosing sensitive business information would undermine the tendering process and have potentially far-reaching consequences for the ability of the Commission to carry out its tasks as set out in Commission Decision C(2020) 4192 that forms the basis of the negotiations.

The Commission is acting in full compliance with all applicable rules regarding financial management.

The steering board has been set up by Article 2 of Commission Decision C (2020) 4192. The steering board includes senior officials from all participating Member States to assist and provide guidance throughout the evaluation process. Each Member State representative signed a confidentiality agreement and absence of conflict of interest statement.”


Photo Credit :

%d bloggers like this: